Share
Dr. Stephen
Nucleus RadioPharma, a next-generation contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals, has appointed Dr. Stephen M. Hahn as Chief Executive Officer.
Dr. Hahn’s leadership underscores the company’s mission to build the infrastructure necessary to expand global patient access to minimally invasive, targeted cancer therapies.
Dr. Hahn brings a unique blend of regulatory, clinical, and operational expertise. He most recently served as CEO-partner at Flagship Pioneering and CEO of Harbinger Health. From 2019 to 2021, he was the 24th Commissioner of the U.S. Food and Drug Administration (FDA), where he oversaw both COVID and non-COVID regulatory affairs.
Prior to the FDA, Dr. Hahn served as Chief Medical Executive at MD Anderson Cancer Center in Houston, one of the world’s leading oncology institutions.
Radiopharmaceuticals are rapidly emerging as a transformative frontier in oncology, offering highly precise, less toxic cancer treatments. Yet patient access remains constrained by fragile isotope supply chains, limited GMP-compliant infrastructure, and insufficient operational capacity. Under Dr. Hahn’s leadership, Nucleus RadioPharma is positioned to address these barriers and set new standards for radiopharmaceutical delivery.
Founded in 2022 through a collaboration between Eclipse and Mayo Clinic, Nucleus has raised US$72 million in funding, with backing from AstraZeneca. The company is building a network of advanced facilities, including sites in Arizona, Pennsylvania, and Minnesota. In his first year, Dr. Hahn will focus on GMP readiness, R&D expansion, and strategic partnerships to accelerate patient access worldwide.
